Patents by Inventor Matthew M. Zhao

Matthew M. Zhao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polymorphs with tyrosine kinase activity
    Patent number: 6872724
    Abstract: The present invention relates to active polymorphs of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: June 26, 2003
    Date of Patent: March 29, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Matthew M. Zhao, Mark T. Bilodeau
  • Active salt forms with tyrosine kinase activity
    Publication number: 20040023978
    Abstract: The present invention relates to orally active salt forms of the mesylate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: June 26, 2003
    Publication date: February 5, 2004
    Inventors: Yu Ren, Shyam B. Karki, Matthew M. Zhao, Mark T. Bilodeau
  • Salt forms with tyrosine kinase activity
    Publication number: 20040023981
    Abstract: The present invention relates to salt forms of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: June 26, 2003
    Publication date: February 5, 2004
    Inventors: Yu Ren, Shyam B. Karki, Matthew M. Zhao, Mark T. Bidodeau
  • Polymorphs with tyrosine kinase activity
    Publication number: 20040023980
    Abstract: The present invention relates to active polymorphs of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: June 26, 2003
    Publication date: February 5, 2004
    Inventors: Matthew M. Zhao, Mark T. Bilodeau
  • Process for making substituted thiazolyl-amino pyridines
    Publication number: 20040023979
    Abstract: The present invention relates to a process for preparing substituted thiazolyl-amino pyridines, which are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases.
    Type: Application
    Filed: June 26, 2003
    Publication date: February 5, 2004
    Inventors: Matthew M. Zhao, Jingjun Yin
  • Process for making 2-amino-5-cyanothiazole compounds
    Publication number: 20040010150
    Abstract: The present invention relates to methods of preparing 2-amino-5-cyanothiazoles, which are useful as intermediates in the preparation of compounds that are known to be useful in the treatment of cancer and other disease by inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases.
    Type: Application
    Filed: June 26, 2003
    Publication date: January 15, 2004
    Inventor: Matthew M. Zhao
  • Process for the synthesis of (2R, 2-alpha-R, 3A)-2-[1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-1, 4-oxazine
    Patent number: 6600040
    Abstract: The present invention is concerned with novel processes for the preparation of (2R, 2-alpha-R, 3a)-2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-1,4-oxazine. This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: July 29, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Karel M. Jos Brands, Fuh-Rong Tsay, Karen M. Conrad, Matthew M. Zhao
  • Process for the synthesis of an endothelin receptor antagonist
    Publication number: 20020107391
    Abstract: The present invention relates to a practical and efficient way to synthesize the compound for the endothelin receptor antagonist involving a Grignard addition and a cyclization reaction to give a desired compound of the general formula shown below: 1
    Type: Application
    Filed: October 18, 2001
    Publication date: August 8, 2002
    Inventors: Lisa F. Frey, Cheng Y. Chen, Jing Li, Zhiguo J. Song, Lushi Tan, Richard D. Tillyer, David M. Tschaen, Matthew M. Zhao
  • Trans-glycosidation process for the synthesis of (2R, 2-alpha-R, 3a)-2-[1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-1,4-oxazine
    Patent number: 6395898
    Abstract: The present invention is concerned with novel processes for the preparation of (2R, 2-alpha-R, 3a)-2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-1,4-oxazine. This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: May 28, 2002
    Assignee: Merck & Co. Inc.
    Inventors: James M. McNamara, Matthew M. Zhao
  • Process for the syntehesis of (2R, 2-alpha-R, 3A) - 2- [1- (3, 5-bis(trifluoromethyl) phenyl) ethoxy] -3- (4-fluorophenyl) -1, 4-oxazine
    Publication number: 20020052494
    Abstract: The present invention is concerned with novel processes for the preparation of (2R, 2-alpha-R, 3a)-2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-1,4-oxazine. This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity.
    Type: Application
    Filed: June 8, 2001
    Publication date: May 2, 2002
    Inventors: Karel M. Jos Brands, Fuh-Rong Tsay, Karen M. Conrad, Matthew M. Zhao
  • Trans-glycosidation process for the synthesis of (2R, 2-alpha-R, 3a) -2-(1- (3,5-bis(trifluoromethyl) phenyl) ethoxy ) -3- (4-fluorophenyl) -1, 4-oxazine
    Publication number: 20020022725
    Abstract: The present invention is concerned with novel processes for the preparation of (2R, 2-alpha-R, 3a)-2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-1,4-oxazine. This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity.
    Type: Application
    Filed: June 8, 2001
    Publication date: February 21, 2002
    Inventors: James M. McNamara, Matthew M. Zhao